Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
|
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
    Ji, Ying
    Wang, Yan-Li
    Xu, Fang
    Jia, Xi-Bei
    Mu, Su-Hong
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Na, Shi-Ping
    Bao, Yu-Shi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [2] Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
    Ji, Ying
    Wang, Yan-Li
    Xu, Fang
    Jia, Xi-Bei
    Mu, Su-Hong
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Na, Shi-Ping
    Bao, Yu-Shi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [3] Association of elevated circulating monocyte-platelet aggregates with hypercoagulability in patients with nephrotic syndrome
    Na, Shi-Ping
    Ning, Mei-Liang
    Ma, Ji-Fang
    Liang, Shuang
    Wang, Yan-Li
    Sui, Man-Shu
    Guo, Xiao-Fang
    Ji, Ying
    Lyu, Hui-Yan
    Yuan, Xue-Ying
    Bao, Yu-Shi
    THROMBOSIS JOURNAL, 2024, 22 (01):
  • [4] Hypercoagulability and Nephrotic Syndrome
    Gigante, Antonietta
    Barbano, Biagio
    Sardo, Liborio
    Martina, Paola
    Gasperini, Maria L.
    Labbadia, Raffaella
    Liberatori, Marta
    Amoroso, Antonio
    Cianci, Rosario
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 512 - 517
  • [5] HYPERCOAGULABILITY IN NEPHROTIC SYNDROME
    Sattler, Lindsey
    Wrenn, Katherine
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S531 - S532
  • [6] HYPERCOAGULABILITY IN CHILDHOOD NEPHROTIC SYNDROME
    ANDRASSY, K
    MEHLS, O
    KODERISCH, J
    RITZ, E
    MONATSSCHRIFT KINDERHEILKUNDE, 1984, 132 (10) : 815 - 815
  • [7] Elevated Factor VIII Activity In Patients With Hypercoagulability Syndrome
    Gonzalez, F.
    Paredes, Hanrry J.
    BLOOD, 2013, 122 (21)
  • [8] BIVENTRICULAR THROMBOSIS IN NEPHROTIC SYNDROME WITH HYPERCOAGULABILITY AND EOSINOPHILIA
    DANCHIN, N
    NEIMANN, JL
    DELIGNY, BH
    GODENIR, JP
    MOREL, O
    KESSLER, M
    CHERRIER, F
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1985, 78 (02): : 271 - 274
  • [9] Hypercoagulability and preventive mechanisms in childhood nephrotic syndrome
    Kavakli, K
    Erkayin, N
    Mir, S
    Aydinok, Y
    THROMBOSIS AND HAEMOSTASIS, 1999, : 317 - 317
  • [10] HYPERCOAGULABILITY, INTRAGLOMERULAR COAGULATION, AND THROMBOEMBOLISM IN NEPHROTIC SYNDROME
    SAGRIPANTI, A
    BARSOTTI, G
    NEPHRON, 1995, 70 (03) : 271 - 281